Clinico-demographic features among telomere maintenance glioblastoma subtypes
| Demographics | Telomere Maintenance Subtype | Pearson χ2 (or F-Ratio) and P Valuesa | ||
|---|---|---|---|---|
| ALT+/M− (n = 26) | ALT−/M− (n = 92) | ALT−/M+ (n = 56) | ||
| % Male (no.) | 57.7 (15) | 63 (58) | 57.1 (32) | 0.6, .742 |
| Mean age (range), yrs | 45.9 (16–66) | 64.1 (40–81) | 63.2 (39–82) | 34.8, <.001 |
| Median survival, mo | 21.0 | 10.6 | 7.1 | 40.1, <.001 |
| % Treated with at least 4 cycles of temozolomide (no.) | 42.3 (11) | 38 (35) | 32 (18) | 0.63, .629 |
| % Treated with radiotherapy (no.) | 84.6 (22) | 78.3 (72) | 92.9 (52) | 5.5, .064 |
| Type of surgery | ||||
| Biopsy, % (no.) | 15.4 (4) | 24 (22) | 16 (9) | 37.9, <.0001 |
| Near total, % (no.) | 76.9 (20) | 61 (56) | 27.3 (15) | |
| Partial | 8 (2) | 15.2 (14) | 56.4 (31) | |
| MGMT promoter methylation status, % (no.) | 61.5 (16) | 45 (36) | 48 (25) | NS |
| IDH1 and IDH2 mutation status, % (no.) | 73 (19) | 9 (8) | 5 (3) | 67, <.0001 |
Note:—NS indicates not significant.
↵a Statistical comparisons were made between 3 groups: ALT+/M−, ALT−/M−, and ALT−/M+.